Immunomedics, Inc. (IMMU): Price and Financial Metrics


Immunomedics, Inc. (IMMU)

Today's Latest Price: $87.86 USD

0.04 (0.05%)

Updated Oct 22 8:09pm

Add IMMU to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

See all "A" rated Strong Buy stocks

IMMU Stock Summary

  • IMMU's price/sales ratio is 996.56; that's higher than the P/S ratio of 99.41% of US stocks.
  • As for revenue growth, note that IMMU's revenue has grown 6,804.75% over the past 12 months; that beats the revenue growth of 99.77% of US companies in our set.
  • The volatility of Immunomedics Inc's share price is greater than that of 95.91% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to IMMU, based on their financial statements, market capitalization, and price volatility, are ZLAB, ITCI, LIFE, CBMG, and CANF.
  • Visit IMMU's SEC page to see the company's official filings. To visit the company's web site, go to www.immunomedics.com.

IMMU Stock Price Chart Interactive Chart >

Price chart for IMMU

IMMU Price/Volume Stats

Current price $87.86 52-week high $87.93
Prev. close $87.82 52-week low $8.80
Day low $87.59 Volume 15,318,600
Day high $87.93 Avg. volume 4,013,131
50-day MA $67.34 Dividend yield N/A
200-day MA $37.03 Market Cap 20.31B

Immunomedics, Inc. (IMMU) Company Bio


Immunomedics, Inc. focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company was founded in 1982 and is based in Morris Plains, New Jersey.


IMMU Latest News Stream


Event/Time News Detail
Loading, please wait...

IMMU Latest Social Stream


Loading social stream, please wait...

View Full IMMU Social Stream

Latest IMMU News From Around the Web

Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.

Gilead Makes A Sizeable Bet On Immunomedics

Trodelvy. Source: Fierce Pharma Gilead (GILD) just unpacked part of its $21 billion war chest to acquire Immunomedics (IMMU) for $21 billion. "The agreement will provide Gilead with TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate ((ADC)) that was granted accelerated approval by the U.S. Food and Drug Administration...

Shock Exchange on Seeking Alpha | September 26, 2020

Immunomedics' trodelvy shows 27% response rate in urothelial cancer

Immunomedics (IMMU) announced positive results from cohort 1 (n=113) of cisplatin-eligible patients in Phase 2 TROPHY U-01 study of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC).Results confirmed the interim findings and prior Phase 1/2 study results showing Trodelvy has significant activity and is safe in patients with heavily-pretreated mUC...

Seeking Alpha | September 21, 2020

The Week Ahead In Biotech: Conference Presentations, IPOs In The Mix

Biotech stocks found themselves among gains in the week ended Sept. 18, with conference presentations, IPO news flow and updates on coronavirus vaccine/antibody candidates catalyzing some strong moves. A big-ticket M&A was announced at the start of the week. Gilead Sciences Inc. (NASDAQ: GILD agreed to buy Immunomedics Inc. (NASDAQ: IMMU ), which has a commercial antibody drug conjugate in the market. Three biopharma companies and a dialysis equipment maker debuted on Wall Street, with the former group raising combined gross proceeds of $522 million. Here're the catalytic events for the unfolding week: Conferences 56th annual meeting of the European Association for the Study of Diabetes, or EASD: Sept. 21-25 2020 American Academy of Neurology Science Highlights: Sept. 23-24 14th annual ...

Benzinga | September 20, 2020

Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers

Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM)

GlobeNewswire | September 18, 2020

Wachtell regains top M&A perch, leapfrogging Latham for now

With the fourth quarter fast approaching, Wachtell, Lipton, Rosen & Katz has passed Latham & Watkins to once again become the top U.S. M&A adviser based on transaction value for 2020, after advising biotech company Immunomedics Inc on its agreement to be acquired by Gilead…

Reuters | September 17, 2020

Read More 'IMMU' Stories Here

IMMU Price Returns

1-mo N/A
3-mo N/A
6-mo 113.20%
1-year 366.84%
3-year 412.30%
5-year 4,337.37%
YTD N/A
2020 0.00%
2019 48.28%
2018 -11.70%
2017 340.33%
2016 19.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7822 seconds.